Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions

Phase 1 Completed 37 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-387 in healthy volunteers under fasting conditions.

Timeline

Start: 2022-09-16
Primary completion: 2022-09-26
Completion: 2022-10-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-387	Unknown	—	—
Subject	D484	Unknown	—	—

Indications

No indication recorded.